CEL-SCI Corporation (CVM)
Market Cap | 102.79M |
Revenue (ttm) | n/a |
Net Income (ttm) | -36.87M |
Shares Out | 43.74M |
EPS (ttm) | -0.85 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 61,080 |
Open | 2.26 |
Previous Close | 2.24 |
Day's Range | 2.26 - 2.38 |
52-Week Range | 1.88 - 6.14 |
Beta | 1.71 |
Analysts | Buy |
Price Target | 10.71 (+356.72%) |
Earnings Date | Feb 14, 2023 |
About CVM
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CVM stock is "Buy." The 12-month stock price forecast is $10.71, which is an increase of 356.72% from the latest price.
News

CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Extension
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ECHNO--CEL-SCI's Multikine Phase 3 cancer study shows 43% survival extension.

CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ECHNO--CEL-SCI to present new Phase 3 data at European Congress on Head & Neck Oncology.

CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corpora...

CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2022, as well as key clinical and corporate developments.

CEL-SCI Corporation Issues Letter to Shareholders
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

CEL-SCI'S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
VIENNA, Va.

CEL-SCI'S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO22--CEL-SCI Corporation (NYSE American: CVM) today announced two poster presentations were delivered at the European Society for Medical Oncology (EMSO) annu...

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI corporation announces Phase 3 Multikine head and neck cancer results posted on clinicaltrials.gov.

CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2022, as well as key clinical and corporate d...

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pi...

CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces Reddit AMA with Geert Kersten.

CEL-SCI Corporation to Present at LD Micro Invitational
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation to Present at LD Micro Invitational.

CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ASCO22--CEL-SCI presents Phase 3 Multikine head and neck cancer data at ASCO.

CEL-SCI Announces Publication of ASCO 2022 Abstracts
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces publication of ASCO 2022 abstracts.

CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI corporation reports second quarter fiscal 2022 financial results.

CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces acceptance of abstracts to ASCO 2022.

CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports first quarter fiscal 2022 financial results.

CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2021 financial results and clinical & corporate developments.

CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation completes commercial-scale buildout of Multikine manufacturing facility.

CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2021 financial results.

Discussion of Results of CEL-SCI's Phase 3 Trial Is Now Available
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--The discussion of the results of CEL-SCI's Phase 3 Trial is now available.

Why CEL-SCI Shares Are Getting Hammered Today
CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in grou...

CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021

CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today
Today, the trial results reported by Cel-Sci missed the mark, and investors are pricing in additional risks with CVM stock. The post CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today appea...

CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients
CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell carcinoma of the head and neck (SCCHN). In ...